To the Editor:
Serious flaws in the design of the European Coronary Surgery Study' raise questions as to the validity of its conclusions.
Patients were retained in their original randomly allocated treatment groups, creating a strong bias against surgery: Once randomized to surgery, patients who did not undergo operation were analyzed as though they had. Likewise, patients randomized to medical treatment were analyzed as "medical" even if they underwent surgery (22.3% of the medical group).
The unreasonable nature of such a study becomes clear if one applies this design to the study of a hypothetical drug:
Once a decision is made to administer drug A to a patient, any untoward outcome is called a toxic effect of the drug even if the patient never received it. Furthermore, although 22% of patients in the control group are being given drug A, they are still counted as controls.
Such a design violates the basic principle of the controlled clinical trial in which "the two series, under simultaneous investigation, are as alike as possible in every respect except that in one series, the patients receive the new drug or procedure, while in the other, they receive the control drug or procedure. "2 It is not sufficient for the authors to state that the "policy of surgery" is being compared with the "policy of medical treatment," as this does not address the study question: whether coronary bypass surgery prolongs life in patients with stable angina that in past practice has not been considered severe enough to warrant surgery.'
A poorly designed study is worse than no study at all, as it gives unsupported bias the authority of scientific fact. If a study design is inadequate to answer the question at hand, no conclusions at all may be drawn.
GERALD Dr. Weinstein's comment regarding the report of the European Coronary Surgery Study (ECS Study)' brings up the chief source of misunderstanding about the logic of trial design: dealing with treatment deviants in the analysis of results. Before responding to his query, it must be emphasized that there are no ethically justifiable and statistically valid rules of design that can completely prevent deviations from randomized treatment, especially invasive one. A group of British and American 2 statisticians, among many others, have clearly demonstrated that when departures from protocols are necessary, it is seriously wrong to exclude deviants, from the analysis or to include them up to the date of deviation. The groups that deviate from their respective treatment may be so different between themselves in their respective chances of long survival that the treatment comparison in the remaining patients will be severely biased. Comparisons that omit protocol deviants cannot be tested statistically.2 In the ECS Study, "medical" patients who received surgery had developed intractable angina despite adequate medical management, and the "surgical" patients who were not operated on had changed their originally positive attitude toward surgery or died before operation could be performed. According to the ethics of sound medical practice, these protocol deviations were unavoidable.
Dr. Weinstein thinks that it is insufficient to compare the policy of no surgery (where the primary intention is to treat anginal pain medically) with the policy of surgery (primarily aiming to prevent premature deaths) "as this does not address the study question. " We have, however, clearly stated1. 3 that no factors other than surgery can explain the observed increased survival with the policy of surgery, which, for instance, implies that the differences in survival emerged not because of protocol deviants but in spite of them. The principle question of our study is clearly addressed and convincingly answered: Coronary bypass surgery prolongs life in patients with stable angina that in past practice has not been considered severe enough to warrant surgery.
Please note the following correction in our report ' The authors reply:
To the Editor:
It is well known that acute myocarditis may develop after various virus infections in man and experimental animals. The aim of our study was to determine if dilatation and hypertrophy of the heart develop in the chronic stage of viral infection. As reported previously,' congestive heart failure developed in the acute stage of infection with EMC virus in BALB/c mice, in which little calcification was noted. Although these mice did not develop cardiac dilatation or hypertrophy in the chronic stage, we believe that these mice could not survive the acute stage of infection because myocarditis was too severe.
